KI has received per diem, including speaking fees, from Janssen Pharmaceutical, and Ono Pharmaceutical; has received research funding from AstraZeneca, AbbVie, Incyte Biosciences Japan, Bristol Myers Squibb, Eisai, Novartis Pharma, Janssen Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Chugai Pharmaceutical, BeiGene, Genmab, Loxo Oncology, Otsuka Pharmaceutical, and Regeneron Pharmaceuticals. ND has received research funding from AbbVie.. YH, MO, FH, and EY have no conflict of interests to declare.